ACM
RGNX icon

ADAR1 Capital Management’s Regenxbio RGNX Stock Holding History

ADAR1 Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,800
Closed -$138K – 244
2024
Q4 		$138K Hold
17,800
– – 0.03% 170
2024
Q3 		$187K Buy
+17,800
New +$217K 0.03% 165

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ADAR1 Capital Management's RGNX Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Regenxbio (RGNX) stake by 69% in Q1 2026, selling an estimated $1.06M and leaving 44,416 shares worth $372K. The position accounts for 0.02% of the portfolio, ranked #224.

ADAR1 Capital Management first reported a position in RGNX in Q1 2024 and has held it in 9 quarters since. The position peaked at $5.97M in Q3 2024. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • ADAR1 Capital Management held 44,416 shares of Regenxbio worth $372K as of Q1 2026.
  • ADAR1 Capital Management sold 100,432 Regenxbio shares in Q1 2026, an estimated $1.06M.
  • Regenxbio made up 0.02% of ADAR1 Capital Management's portfolio in Q1 2026, its #224 holding.
  • ADAR1 Capital Management first reported a position in Regenxbio in Q1 2024 and has held it in 9 quarters since.
  • ADAR1 Capital Management's Regenxbio position peaked at $5.97M in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.